How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/slow-progression-of-coronary-artery-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Slow Progression of Coronary Artery Disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Slow Progression of Coronary Artery Disease (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Slow Progression of Coronary Artery Disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lipitor	Atorvastatin Calcium	Pfizer	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Lescol	FLUVASTATIN	Novartis	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
Mevacor	LOVASTATIN	Merck & Co.	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01
Zocor	simvastatin	Merck & Co.	HMG-CoA Reductase Inhibitor [EPC]	Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Myoinositol	Myoinositol	University of Colorado, Denver

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 2 drugs in Slow Progression of Coronary Artery Disease
· 1 drug in Slow Progression of Coronary Artery Disease
Novartis · 1 drug in Slow Progression of Coronary Artery Disease
Pfizer · 1 drug in Slow Progression of Coronary Artery Disease
Pfizer Inc. · 1 drug in Slow Progression of Coronary Artery Disease
University of Colorado, Denver · 1 drug in Slow Progression of Coronary Artery Disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Slow Progression of Coronary Artery Disease:

Cite this brief

Drug Landscape (2026). Slow Progression of Coronary Artery Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/slow-progression-of-coronary-artery-disease. Accessed 2026-06-10.

Slow Progression of Coronary Artery Disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing